[(18)F]FAPI-04 PET/CT 在疑似复发性肝细胞癌中的诊断效能：与增强 CT/MRI 的前瞻性比较

To evaluate the diagnostic performance of [ 18 F]FAPI-04 PET/CT in differentiating hepatocellular carcinoma (HCC) recurrence from treatment-induced lesions (TILs) after therapy and compare it with contrast-enhanced CT/MRI (Ce-CT/MRI).

Patients with suspected HCC recurrence after resection or local-regional therapy, who underwent Ce-CT/MRI and [ 18 F]FAPI-04 PET/CT, were prospectively enrolled. For each patient or lesion, a three-point-scale (positive, negative, or equivocal) was assigned to Ce-CT/MRI and [ 18 F]FAPI-04 PET/CT. The diagnostic performances of Ce-CT/MRI, [ 18 F]FAPI-04 PET/CT, and their combination were compared by McNemar's test, with histopathology or radiographic follow-up as a reference standard. The maximum standardized uptake value (SUV max ) and lesion-to-background ratio (LBR) of lesions derived from [ 18 F]FAPI-04 PET/CT were analyzed, and the cut-off points for distinguishing between HCC recurrence and TILs were calculated.

A total of 44 patients with 129 lesions were analyzed, of which 31 patients (91 lesions) were proved to be recurrent HCC and 38 lesions were TILs. On lesion-based analysis, the combination of [ 18 F]FAPI-04 PET/CT with Ce-CT/MRI demonstrated superior sensitivity (86.8% vs. 70.3% vs. 72.5%), specificity (89.5% vs. 42.1% vs. 52.6%), and accuracy (87.6% vs. 62.0% vs. 66.7%) compared to Ce-CT/MRI and [ 18 F]FAPI-04 PET/CT alone (all P < 0.001). The combination altered therapy management in 22.7% of patients. On semiquantitative analysis, the SUV max and LBR of [ 18 F]FAPI-04 PET in HCC recurrence (n = 91) were significantly higher than those in TILs (n = 38) (SUV max : 8.1 vs. 3.65, P < 0.001; LBR: 5.4 vs. 1.9, P < 0.001). Using cutoff points of 5.1 for SUV max and 2.3 for LBR, [ 18 F]FAPI-04 PET/CT exhibited high sensitivity and specificity in differentiating recurrent HCC from TILs, with 83.5%, 78.9% and 96.2%, 63.2%, respectively.

The combination of [ 18 F]FAPI-04 PET/CT with Ce-CT/MRI significantly improved diagnostic sensitivity, specificity, and accuracy in differentiating recurrent HCC from TILs. [ 18 F]FAPI-04 PET may be a promising imaging modality in detecting recurrent HCC. TRIAL REGISTRATION: clinicaltrials.gov: NCT05485792.